Piramal Healthcare

Company likely to takeover ASE

Posted by : Guest

View full thread (1 messages)

Tracked by: 0 Boarder

as per market talk company is likley to takever baroda based pharma and real estate company ASE as ASE is only Pharma and Real estate company with face value of 10 rupees and probable turnaround and splitting chances of it's shares in 1-2 rupees....

Company likely to takeover ASE

Posted by : Guest

View full thread (1 messages)

Tracked by: 0 Boarder

As per market talk company is likely to takeover baroda based Pharma and real estate company ASE ,as ASE is only Pharma and Real estate company with 10 rupee face value and probable turnaround this year and a future chances of splitting in 1-2 ruppes,looking to it ASE takeover can prove gold mine for the company. ASE shareholders will also benifit with professional management. ...

NSE Announcements on Piramal Health

Posted by : MMB Messenger
Price when posted : [Piramal Health - BSE:Rs. 306.55 NSE:Rs. 312.50 when posted]

View full thread (1 messages)

Tracked by: 0 Boarder

Piramal Healthcare Limited has informed the Exchange that "Mr. N. Santhanam - Executive Director and Chief Financial Officer, has been appointed as Chief Operating Officer on the Board of the Company. Consequent to the above, Mr. Rajesh Laddha - President (Finance) now holds independent charge of the Finance function of the Company"....

BSE Announcements on Piramal Health

Posted by : MMB Messenger
Price when posted : [Piramal Health - BSE:Rs. 304.25 NSE:Rs. 304.75 when posted]

View full thread (1 messages)

Tracked by: 0 Boarder

Piramal Healthcare Ltd has informed BSE that Mr. N Santhanam - Executive Director and Chief Financial Officer, has been appointed as Chief Operating Officer on the Board of the Company.

Consequent to the above, Mr. Rajesh Laddha - President (Finance) now holds independent charge of the Finance function of the Company....

Piramal Healthcare Acquires German Brands

Posted by : rishikul
Price when posted : BSE: Rs 318.90 ( -0.50 % ), NSE: Rs. 318.60 ( -0.50 % )

View full thread (1 messages)

Tracked by: 0 Boarder

Aims to become a global leader in polygeline-based blood plasma expansion products

Piramal Healthcare Limited, one of India's largest pharmaceutical and healthcare companies, and part of the Piramal Group, announced the completion of a definitive agreement with PlasmaSelect AG, Germany (PlasmaSelect), to acquire PlasmaSelect's polygeline-based blood plasma products marketed under the brand name 'Haemaccel' in over 38 countries. In addition, PlasmaSelect also markets the product under the brand name 'Emagel' in Italy and 'Solucel' in Venezuela. This acquisition is intended to bring global leadership to Piramal Healthcare's polygeline-based blood plasma expansion products. Piramal Healthcare currently markets the products under the brand name 'Haemaccel' in India and under the brand name 'Haemageline' in 17 other countries. Commenting on the acquisition, Ajay Piramal, Chairman, Piramal Group said, "Over the years, we have recognised the compelling potential of the global critical care business. We aspire to become a leading global player in this business with our worldwide distribution network and state-of-the-art manufacturing facilities in India." Blood plasma expansion products are life-saving infusion pharmaceuticals that help maintain blood plasma volume until blood transfusion can be administered to the patient, in the event of blood loss. These products also serve a range of other critical care needs in hospitals and critical care facilities. In 1998, Piramal Healthcare bought Haemaccel-related business in the Indian market along with the manufacturing facility in Mumbai from sanofi-aventis, the originator company of Haemaccel. In 2004, sanofi-aventis sold its Haemaccel-related rights in 76 countries and its manufacturing facility at Marburg, Germany, to PlasmaSelect AG. The total yearly revenues of Haemaccel and associated brands of Piramal Healthcare and PlasmaSelect together are 9.1 million euros, at current exchange rates. Blood plasma expansion products are a part of the global critical care business division of Piramal Healthcare. The global critical care division markets a range of important hospital pharmaceuticals, including halothane / isoflurane inhalation anaesthetics. The acquisition is consistent with Piramal healthcare's objective of growing its global critical care business. Piramal Healthcare will pay cash consideration of 7.7 million euros for the transaction. The transaction includes the brand rights, contracts, registrations, dossiers and know-how relating to haemaccel and associated brands. It excludes the manufacturing facility of PlasmaSelect at Marburg, Germany. This capacity would be able to service the expanded Haemaccel sales. PlasmaSelect will continue to manufacture Haemaccel as per Piramal Healthcare's requirements to facilitate orderly migration of manufacturing to the new facility at Baddi, Himachal Pradesh....